Article citationsMore>>
Nowell, S.A., Ahn, J.Y., Rae, J.M., Scheys, J.O., Trovato, A., Sweeney, C., MacLeod, S.L., Kadlubar, F.F. and Ambrosone, C.B. (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Research and Treatment, 91, 249-258.
doi:10.1007/s10549-004-7751-x
has been cited by the following article:
-
TITLE:
More Stable, More Estrogenic: The SERM-ERα LBD Complex
AUTHORS:
Li Gao, Yaoquan Tu, Leif A. Eriksson
KEYWORDS:
Breast Cancer; Tamoxifen Resistance; Molecular Dynamics Simulations;
Dihydrobenzoxathiin; SERM
JOURNAL NAME:
Journal of Biophysical Chemistry,
Vol.2 No.3,
August
9,
2011
ABSTRACT: Many synthetic selective estrogen receptor modulators (SERMs) have been cocrystallized with the human estrogen receptor α ligand binding domain (ERα LBD). Despite stabilizing the same canonical inactive conformation of the LBD, most SERMs display different ligand-dependent pharmacological profiles. We show here that increased partial agonism of SERMs is associated with increased conformational stability of the SERM-LBD complexes, by investigation of dihydrobenzoxathiin-based SERMs using molecular modelling techniques. Analyses of tamoxifen (TAM) and 4-hydroxytamoxifen (OHT) in complex with the LBD furthermore indicates that the conversion of TAM to OHT increases both the affinity to ERα and the partial agonism of the anti-cancer drug, which provides a plausible explanation of the counterintuitive results of TAM therapy.
Related Articles:
-
Inès Ayadi Masmoudi, Amine Masmoudi, Nabil Toumi, Afef Khanfir, Mounir Frikha, Jamel Daoud
-
Aravindh Sivanandan Anand, Annie Joseph, Antony Stanley
-
Zhengkai Zhuang
-
Wei Zhang, Aldo Becciolini, Annibale Biggeri, Paolo Pacini, Colin R. Muirhead
-
Aiat Morsy, Sara H. Hammouda, Samir Shehata